Posted by Jack Davis on April 10th, 2009 at 4:30 pm | Categorized as A.P. Pharma, Departures, Docu-Drama | Tagged as A.P. Pharma, Arthur Taylor, Departures, Kevin Tang, Peter Riepenhausen, Toby Rosenblatt
AP Pharma said today in a filing that it’s board was notified by two of its directors on Tuesday that they would not seek re-election to the board when their terms expire at the company’s next annual meeting, scheduled for May 27.
Peter Riepenhausen is stepping down after after 18 years on the company’s board, where he served on the Read the rest of this entry »
Leave a comment
Posted by Jack Davis on February 9th, 2009 at 4:00 pm | Categorized as A.P. Pharma | Tagged as A.P. Pharma
AP Pharma, the Redwood City pharmaceutical company developing drug-delivery technology, named its largest shareholder to its board of directors effective Sunday. His appointment expands the company’s board size to eight members.
Tang’s investment firm, San Diego-based Tang Capital Management, last reported holding 7.8 million shares of AP Pharma, or about a quarter of all its shares outstanding. The next largest Read the rest of this entry »
Leave a comment
Posted by Jack Davis on November 5th, 2008 at 1:21 pm | Categorized as A.P. Pharma, Executive Pay, Layoffs | Tagged as A.P. Pharma, Biotechnology, Credit crisis, Executive Pay, Layoffs
AP Pharma, the Redwood City specialty pharmaceutical company, has begun rationing its resources to ensure its survival “in response to the deterioration of the overall economic environment and the financial markets”, the company said in a release early Wednesday.
The steps include Read the rest of this entry »
Leave a comment
Posted by Jack Davis on October 7th, 2008 at 8:29 pm | Categorized as A.P. Pharma, Poison pill, Private equity | Tagged as A.P. Pharma, Poison pill, Private equity
AP Pharma decided to increase the amount of shares its biggest shareholder may accumulate before the company would need to swallow its poison pill, er, shareholder rights plan in order to deter him from gaining control, according to a regulatory filing Tuesday.
On Oct. 1, AP Pharma (ticker: APPA) amended its Preferred Shares Rights Agreement dated Dec. 18, 2006, to allow Kevin Tang and his affiliated companies to acquire up to Read the rest of this entry »
Leave a comment
Posted by Jack Davis on July 10th, 2008 at 3:48 pm | Categorized as A.P. Pharma, Executive Pay, Options | Tagged as A.P. Pharma, Executive Pay, Stock options
The welcome wagon at AP Pharma rolled out a huge option award Monday to its new chief executive, Ronald Prentki.
How big was it? Read the rest of this entry »
Leave a comment